Gray market weight loss drugs are harming Washingtonians
As the demand for GLP-1 medications grows, gaps in insurance coverage and persistent weight stigma are driving vulnerable patients toward dangerous counterfeit drugs. Legislators must act to protect patients, secure the drug supply, and ensure safe, equitable access to evidence-based obesity care.

Gray market weight loss drugs are harming Washingtonians - NPI's Cascadia Advocate
As the demand for GLP-1 medications grows, gaps in insurance coverage and persistent weight stigma are driving vulnerable patients toward dangerous counterfeit drugs. Legislators must act to protect patients, secure the drug supply, and ensure safe, equitable access to evidence-based obesity care.






